Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database.
Jaykaran CharanSiddhartha DuttaRimplejeet KaurPankaj BhardwajPraveen SharmaSneha AmbwaniIffat JahanAbdullahi Rabiu AbubakarSalequl IslamTimothy Craig HardcastleNor Azlina A RahmanHalyna LugovaMainul HaquePublished in: Expert opinion on drug safety (2021)
Neutropenia, superinfections, reactivation of latent infections, hepatitis, and cardiac abnormalities were common ADEs observed that necessitate proper monitoring and reporting.